First Diovan Investigational Committee Meeting: New Data Discrepancies In Two More Trials
This article was originally published in PharmAsia News
Executive Summary
The Japanese MHLW’s Study Committee on Clinical Research regarding Hypertension Treatment held its first meeting Aug. 9 after allegations of data manipulation by Novartis in valsartan trials shocked the nation.